Intranasal Carbetocin Reduces Hyperphagia, Anxiousness, and Distress in Prader-Willi Syndrome: CARE-PWS Phase 3 Trial.

J Clin Endocrinol Metab · 2023 · PMC10271225 · PMID 36633570

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The 2 primary endpoints assessing change in HQ-CT and CY-BOCS for the 9.6-mg carbetocin arm showed numeric improvements vs placebo that did not reach statistical significance; therefore, the trial did not meet its primary endpoint and all other statistical analyses are considered nominal.

also in 111,027 other papers

nominally significantno p-value reported

The primary endpoints showed numeric improvements in both HQ-CT and CY-BOCS which were not statistically significant; however, the 3.2-mg arm showed nominally significant improvements in HQ-CT, PADQ, and CGI-C scores vs placebo.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.